RxDoctor Payments Data

Michael Harder, DO

Family Medicine · Sioux City, IANPI 1427064146

Payments from drug & device makers

$2,141in general payments, 2019–2025

Across 126 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$499
  • Pfizer$268
  • Amgen$236
  • Novo Nordisk$188
  • AstraZeneca$130
  • Nestle Healthcare Nutrition Inc.$101
  • plus $719 from 21 others

What the payments were for

  • Food & beverage$2,08397%
  • Education$583%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,141 in reported general payments places this provider in the 85th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$342,417
Medicare patients
488
Services billed
9,714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban86$71,820
OzempicSemaglutide50$69,445
JanuviaSitagliptin Phosphate71$46,346
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$44,232
XareltoRivaroxaban32$33,260
JardianceEmpagliflozin33$27,759
MyrbetriqMirabegron42$27,265
Breo ElliptaFluticasone/Vilanterol28$13,538
JanumetSitagliptin Phos/Metformin Hcl16$13,527
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$12,360
TradjentaLinagliptin14$8,118
Atorvastatin Calcium853$5,307
MovantikNaloxegol Oxalate13$4,706
SymbicortBudesonide/Formoterol Fumarate20$4,574
Midodrine Hcl28$4,484

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$268$71,82086 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$51$70,13090 claims
Novo NordiskOzempic$188$69,44550 claims
MerckJanuvia, Janumet$16$59,87387 claims
Boehringer IngelheimJardiance, Tradjenta$27$35,87747 claims
Astellas Pharma US IncMyrbetriq$58$27,26542 claims
AstraZenecaSymbicort$130$4,57420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Sioux City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →